CRISPR Therapeutics Receives $89 Million in Series A and B Financing Rounds

On April 29, 2015, CRISPR Therapeutics, a biopharmaceutical company focused on translating CRISPR-Cas9 gene-editing technology into transformative medicines, announced that it has raised a total of $89 million in a Series A and Series B round of financing, with $35 million of new funding from Series A and $29 million from Series B.

The two financings were led by SR One (the independent corporate venture capital arm of GlaxoSmithKline) and Celgene Corporation, and included new investors New Enterprise Associates (NEA) and Abingworth, as well as the company's founding investor, Versant Ventures. Wilson Sonsini Goodrich & Rosati partner Dan Koeppen and venture counsel Meg Burton advised SR One, NEA, and Abingworth in the transaction.

For more information, please click here.